Zoetis Stock (NYSE:ZTS)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$72.45

52W Range

$71.47 - $161.77

50D Avg

$86.24

200D Avg

$117.33

Market Cap

$31.36B

Avg Vol (3M)

$6.87M

Beta

0.74

Div Yield

$2.06 (2.75%)

ZTS Company Profile


Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Show More

Industry

Drug Manufacturers - General

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

13,800

IPO Date

Feb 01, 2013

Website

ZTS Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Fish$286.00M$242.00M$220.00M
Horses$6.28B$5.99B$5.29B
Poultry$432.00M$527.00M$524.00M
Swine$466.00M$516.00M$543.00M
Dogs and Cats$304.00M$285.00M$285.00M
Cattle$1.49B$1.53B$1.50B
Medicated Feed Additives--$354.00M
Anti-infective Products--$1.06B
Contract Manufacturing and Human Health Diagnostics--$78.00M
Dermatology--$1.43B
Other Non Pharmaceuticals--$254.00M
Vaccines--$1.77B
Total Products and Services--$8.47B
Parasiticides--$1.95B
Other Pharmaceuticals--$1.28B
Animal Health Diagnostics--$376.00M

Fiscal year ends in Dec 25 | Currency in USD

ZTS Financial Summary


Dec 25Dec 24Dec 23
Revenue$9.47B$9.26B$8.54B
Operating Income-$3.39B$3.07B
Net Income$2.67B$2.49B$2.34B
EBITDA-$3.87B$3.69B
Basic EPS$6.03$5.47$5.08
Diluted EPS$6.02$5.47$5.07

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26May 07, 26 | 12:00 AM
Q4 25Feb 12, 26 | 12:00 AM
Q3 25Nov 04, 25 | 8:30 AM

Peer Comparison


TickerCompany
REGNRegeneron Pharmaceuticals, Inc.
ELVElevance Health Inc.
HLNHaleon plc
TAKTakeda Pharmaceutical Company Limited
CORCencora, Inc.
BDXBecton, Dickinson and Company
ARGXargenx SE
CICigna Corporation
IDXXIDEXX Laboratories, Inc.
ELANElanco Animal Health Incorporated